Scott Okuno, MD
Medical Oncology · Rochester, MNNPI 1750367561
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $32,561 of the $47,669 with a category attached, or 68.3%. 8 manufacturers reported payments, led by Boehringer Ingelheim at 54.3% of the total. Reporting peaked in 2024 at $20,099 and has fallen 89.9% since, to $2,024 in 2025.
Across 54 payments — averaging $882.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$26K
- Deciphera Pharmaceuticals Inc.$14K
- EMD Serono, Inc.$4K
- Aadi Bioscience, Inc.$2K
- Bayer$1K
- Daiichi Sankyo Inc.$148
- plus $115 from 2 others
Across 110 payments — averaging $3138.65 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Deciphera Pharmaceuticals Inc.$211K
- Karyopharm Therapeutics Inc.$96K
- Blueprint Medicines Corporation$24K
- Bayer$10K
- Astrazeneca UK Limited$4K
- Merck$132
What the payments were for
- Consulting fees$32,56168%
- Speaking & faculty fees$10,34022%
- Travel & lodging$3,6308%
- Food & beverage$1,0692%
- Education$680%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 20 | $25,883 |
| Deciphera Pharmaceuticals Inc. | 23 | $14,174 |
| EMD Serono, Inc. | 1 | $4,275 |
| Aadi Bioscience, Inc. | 6 | $1,823 |
| Bayer | 1 | $1,250 |
| Daiichi Sankyo Inc. | 1 | $148 |
| AstraZeneca | 1 | $68 |
| Boehringer Ingelheim International GmbH | 1 | $47 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$47,669 in reported general payments places this provider in the 85th percentile of 133 medical oncology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| InlytaAxitinib | 14 | $281,759 |
| RevlimidLenalidomide | 17 | $237,890 |
| ErleadaApalutamide | 17 | $145,926 |
| Lenalidomide | 13 | $129,657 |
| EliquisApixaban | 20 | $18,912 |
| Imatinib Mesylate | 18 | $3,690 |
| Anastrozole | 44 | $603 |
| Prochlorperazine Maleate | 50 | $509 |
| Dexamethasone | 40 | $463 |
| Tamoxifen Citrate | 11 | $400 |
| Oxycodone Hcl | 15 | $288 |
| Potassium Chloride | 17 | $265 |
| Ondansetron Hcl | 38 | $259 |
| Prednisone | 23 | $139 |
| Hydroxyurea | 11 | $132 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Rochester
- Amit MahipalRochester$746K
- Alton SartorRochester$688K
- Ben GeorgeRochester$579K
- Elisabeth HeathRochester$236K
- Matthew GoetzRochester$136K
- Thorvardur HalfdanarsonRochester$86K
- Harry YoonRochester$69K
- Karthik GiridharRochester$66K
- Joleen HubbardRochester$59K
- Lionel Aurelien Kankeu FonkouaRochester$58K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.